Making the Most of Venue In-Concourse Sponsorship Activations

 

Brands spent over $68 Billion in sports, entertainment, cause, and event sponsorship properties in 2021. Were these efforts effective? Did they achieve and deliver the desired results in sponsorship activations? It’s the age-old marketing/sales problem; how much to spend on activities such as venue sponsorship activations when the ability to achieve measurable results is murky, at best.

Manchester City deployed a real-time crowd management platform solution at its Etihad Stadium to gain better insights into crowd movement and density. The platform, provided by WaitTime, an Industry leader in crowd intelligence, utilizes real-time and historical data to give sports organizations and operations staff insight into crowd movement and density.

The value of the data and insights this type of platform provides will help the club reduce queue wait times, reduce congestion, and deliver the right messages and information at the right time to spectators.

In making a case for the importance of delivering smart, data-driven sponsorship activation in stadiums, WaitTime’s Founder & CEO, Zack Klima, says AI supports WaitTime’s innovative software capabilities that improve interaction for venue sponsorship activations.

Zack’s Thoughts on Sponsorship Activations

“If you have a sponsorship activation within a venue, organizations don’t know how many people interact with that. That’s a missing part of the puzzle when it comes to sponsorship. So with our software, we’re able to then monitor how effective an actual in-concourse sponsorship activation is regarding our, regarding their solution and our software.

So providing those numbers back to sponsors to say, hey you paid $200,000 for this sponsorship activation. We then quantified how effective that sponsorship activation was in your venue, which then in return can affect that rate card as you go on. Because certain locations across your concourse, you can almost guarantee them that amount of foot traffic because you can prove it now.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More